Nutrient-gene interaction in human obesity: implications for dietary guidelines

Conditions

Obesity Nutritional, Metabolic, Endocrine Obesity

Christiansen MR, Ureña MG, Borisevich D, Grarup N, Martínez JA, Oppert JM, Sørensen TI, Hansen T, Blaak EE, Kilpeläinen TO.

2021-10-0112 citations

10.1093/ajcn/nqab219

Is abdominal obesity at baseline influencing weight changes in observational studies and during weight loss interventions?

Svendstrup M, Allin KH, Ängquist L, Schnohr P, Jensen GB, Linneberg A, Thuesen B, Astrup A, Saris WHM, Vestergaard H, Sørensen TIA.

2018-11-01

10.1093/ajcn/nqy187

Effect of the interaction between diet composition and the <i>PPM1K</i> genetic variant on insulin resistance and β cell function markers during weight loss: results from the Nutrient Gene Interactions in Human Obesity: implications for dietary guidelines (NUGENOB) randomized trial.

Goni L, Qi L, Cuervo M, Milagro FI, Saris WH, MacDonald IA, Langin D, Astrup A, Arner P, Oppert JM, Svendstrup M, Blaak EE, Sørensen TI, Hansen T, Martínez JA.

2017-08-0227 citations

10.3945/ajcn.117.156281

Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials.

Hjorth MF, Ritz C, Blaak EE, Saris WH, Langin D, Poulsen SK, Larsen TM, Sørensen TI, Zohar Y, Astrup A.

2017-07-0574 citations

10.3945/ajcn.117.155200

TFAP2B influences the effect of dietary fat on weight loss under energy restriction.

Stocks T, Angquist L, Banasik K, Harder MN, Taylor MA, Hager J, Arner P, Oppert JM, Martinez JA, Polak J, Rousseau F, Langin D, Rössner S, Holst C, MacDonald IA, Kamatani Y, Pfeiffer AF, Kunesova M, Saris WH, Hansen T, Pedersen O, Astrup A, Sørensen TI.

2012-08-2728 citations

10.1371/journal.pone.0043212

Interventions

One-day clinical investigation examining responses to high fat test meal in lean and obese subjects followed by randomised, parallel, two-arm, open label, 10-week dietary intervention of two hypo-ener

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Body mass index (BMI) =30 2. White European (by self report) 3. Age 20-50 years 4. Pre-menopausal (women)

Exclusion criteria

Exclusion criteria: 1. Drug-treated hypertension 2. Drug-treated diabetes 3. Drug-treated hyperlipidaemia 4. Drug-treated thyroid disease 5. Use of anorexigenic agents 6. Anti-epileptic drugs 7. Anti-Parkinsonian drugs 8. Use of barbituates, benzodiasapines, beta-blockers, butyrophenones, carbonic anhydrase inhibitors, diuretics, dopamine reuptake inhibitors, digoxin, fibrates, fish oil supplement, glucocorticoids, immunosuppressives, insulin , laxatives, monoamine oxidase (MAO) inhibitors, niacin (>150 mg per day), nicotine, oral hypoglycemics, orlistat, phenothiazines, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, statins, thyroid hormone, triamterene, tricyclic antidepressants, warfarin or zonisamide 9. Surgically-treated obesity 10. Participation in ongoing drug trials 11. Pregnant women 12. Alcohol or drug abuse 13. Weight change of >3 kg within 3 months prior to clinical investigation day

Design outcomes

Primary

Measure	Time frame
Weight loss	—

Secondary

Measure	Time frame
1. Changes in waist circumference 2. Body composition assessed by bio-impedance 3. Fasting blood lipids 4. Insulin and glucose	—

Countries

Czech Republic, Denmark, France, Netherlands, Spain, Sweden, United Kingdom

Outcome results

None listed